{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "VATC|CONTRAST MEDIA|X-RAY CONTRAST MEDIA, IODINATED" in comments (approximate match)
Status:
US Previously Marketed
Source:
HEXABRIX by GUERBET
(1985)
Source URL:
First approved in 1985
Source:
HEXABRIX by GUERBET
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ioxaglate Sodium Meglumine (trade name Hexabrix) is a new low osmolality ionic contrast agent, that used as a diagnostic radiopaque medium. Following intravascular injection, Ioxaglate Sodium Meglumine is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine. The joint spaces as well as the uterus and fallopian tubes may be visualized by the direct injection of the contrast medium into the region to be studied. The usual adult dose for left coronary arteriography is 8 mL (range 2-14 mL) and for right coronary arteriography is 5 mL (range 1-10 mL). The doses may be repeated as necessary Patients may have clinically insignificant ECG changes during the procedure. The following adverse effects have occurred in conjunction with the administration of iodinated intravascular contrast agents for this procedure: hypotension, shock, anginal pain, myocardial infarction, cardiac arrhythmias (bradycardia, ventricular tachycardia, ventricular fibrillation) and cardiac arrest.
Status:
US Previously Marketed
Source:
CHOLOVUE by BRACCO
(1981)
Source URL:
First approved in 1981
Source:
CHOLOVUE by BRACCO
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iodoxamic acid (previously sold under the brand name Cholovue) is an organoiodine compound that was used as a contrast medium. It is intravenous cholecystocholangiographic
agent. It features both a high iodine content as well as several hydrophilic groups.
Status:
US Previously Marketed
Source:
RENOVUE-DIP by BRACCO
(1978)
Source URL:
First approved in 1978
Source:
RENOVUE-DIP by BRACCO
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Iodamide is an ionic monomeric iodinated radiographic contrast medium. It was used in many procedures and may be given intravenously or by other routes, for example by instillation into the bladder or uterus; it has also been used for computed tomography. It is usually given as a 24 to 65% solution of the meglumine salt, or as a mixture of the sodium and meglumine salts; solutions of the sodium salt have also been used. Iodamide is no longer marketed in the US.
Status:
US Previously Marketed
Source:
AMIPAQUE by GE HEALTHCARE
(1978)
Source URL:
First approved in 1978
Source:
AMIPAQUE by GE HEALTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Metrizamide is a glucosamine derivative of metrazoic acid, used as a contrast medium for myelography. Metrizamide is no longer marketed in the US.
Status:
US Previously Marketed
Source:
CHOLEBRINE by MALLINCKRODT
(1973)
Source URL:
First approved in 1973
Source:
CHOLEBRINE by MALLINCKRODT
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Iocetamic acid is a medical diagnostic aid. It is a contrast agent used to enhance structures or fluids during X-ray imaging.
Status:
US Previously Marketed
Source:
ISOPAQUE 440 by GE HEALTHCARE
(1973)
Source URL:
First approved in 1973
Source:
ISOPAQUE 440 by GE HEALTHCARE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Metrizoic acid is a diagnostic radiopaque that usually occurs as the sodium salt. The mechanism of action of metrizoic acid is as a X-Ray Contrast Activity.
Status:
US Previously Marketed
Source:
BILOPAQUE by GE HEALTHCARE
(1969)
Source URL:
First approved in 1969
Source:
BILOPAQUE by GE HEALTHCARE
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Tyropanic acid and its salt sodium tyropanoate are radiocontrast agents used in cholecystography (X-ray diagnosis of gallstones). Tyropanic acid is sold under the trade names Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones to produce a visible image. After injection it is rapidly excreted into the bile.
Status:
US Previously Marketed
Source:
HYTRAST IOPYDOL by FOUGERA
(1962)
Source URL:
First approved in 1962
Source:
HYTRAST IOPYDOL by FOUGERA
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Iopydol is an X-ray contrast medium used in conjunction with iopydone as the proprietary preparation, Hytrast, for the bronchography.
Status:
US Previously Marketed
Source:
RETROPAQUE by WINTHROP
(1959)
Source URL:
First approved in 1959
Source:
RETROPAQUE by WINTHROP
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Methiodal is used in lumbar myelography as a contrast agent.
Status:
First approved in 1954
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Propyliodone (INN, trade name Dionosil) is a molecule used as a contrast medium. It was developed by a team at Imperial Chemical Industries in the late 1930s. Propyliodone used as radiopque medium for brochographic use. When directly instilled into the bronchi resulting in well-defined bronchograms for atleast 30 min. Because of its toxicity, Propyliodone should only be used if absolutely essential. It is of Synthetic origin and belongs to Iodinated Radio-opaque Compounds. It belongs to Radiopaque Agents pharmacological group on the basis of mechanism of action and also classified in Diagnostic Aids pharmacological group. Oral absorption of Propyliodone is found to be 101% and metabolism is reported Lungs and Gut wall. Propyliodone is primarily indicated in conditions like Paget's disease of bone, Radiological contrast agent. Propyliodone produces potentially life-threatening effects which include Fever, Anaphylaxis, Repiratory obstruction, Cerebral embolization, which are responsible for the discontinuation of Propyliodone therapy. The signs and symptoms that are produced after the acute overdosage of Propyliodone include Airway obstruction. The symptomatic adverse reactions produced by Propyliodone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fever, Malaise, Nausea and vomiting, Aching joints.